Video

Dr. Reidy-Lagunes on FDA Approval of Telotristat Ethyl for Carcinoid Syndrome

Author(s):

Diane Reidy Lagunes, MD

Diane Reidy-Lagunes, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of telotristat ethyl (Xermelo) as a treatment for carcinoid syndrome in patients with metastatic neuroendocrine tumors (NETs).

Diane Reidy-Lagunes, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of telotristat ethyl (Xermelo) as a treatment for carcinoid syndrome in patients with metastatic neuroendocrine tumors (NETs).

Related Videos
Michael R. Bishop, MD
Lori A Leslie, MD
Andrew Ip, MD
Mansi R. Shah, MD
Elizabeth Buchbinder, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Alec Watson, MD
Sagar D. Sardesai, MBBS
Ashkan Emadi, MD, PhD
Matthew J. Baker, PhD
Related Content
Updates and Advances in Early Stage Breast Cancer
April 5th 2023

Updates and Advances in Early Stage Breast Cancer

Manali Kamdar, MD
December 11th 2021

Dr. Kamdar on the Results of the TRANSFORM Trial in Relapsed/Refractory LBCL

Brandon Blue, MD
October 1st 2021

Dr. Blue on the Utility of Carfilzomib in Relapsed/Refractory Multiple Myeloma

Randall Shares How Postoperative Radiotherapy Retains a Role in Soft Tissue Sarcoma
July 29th 2020

Randall Shares How Postoperative Radiotherapy Retains a Role in Soft Tissue Sarcoma

Dr. Jacobson on the Benefit of Axi-Cel in Relapsed/Refractory Follicular Lymphoma
June 11th 2020

Dr. Jacobson on the Benefit of Axi-Cel in Relapsed/Refractory Follicular Lymphoma

Dr. Katz on Determining Low-Risk Disease in Prostate Cancer
June 2nd 2020

Dr. Katz on Determining Low-Risk Disease in Prostate Cancer